Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy

Neuromuscular Disorders

Volumn 22, Issue 12, 2012, Pages 1040-1045

  Mayo, A L ^a   Craven, B C ^a,b   McAdam, L C ^c,d   Biggar, W D ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL   (Canada)

Author keywords

Bone mineral density; Deflazacort; Duchenne Muscular Dystrophy; Fractures

Indexed keywords

CALCIUM; DEFLAZACORT; FAT; VITAMIN D;

ADOLESCENT; ARTICLE; BIOACCUMULATION; BODY FAT; BONE DENSITY; BONE SCINTISCANNING; CHILD; CHILD HEALTH; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; DUAL ENERGY X RAY ABSORPTIOMETRY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; LEG FRACTURE; LIPID COMPOSITION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SPINE FRACTURE; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WALKING DIFFICULTY;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BODY HEIGHT; BONE AND BONES; BONE DENSITY; CHILD; FRACTURES, BONE; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREGNENEDIONES; QUALITY OF LIFE; RISK FACTORS; TIME FACTORS;

EID: 84870393032     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.06.354     Document Type: Article

References (35)

1. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, Part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9:77-93.
2. Biggar W.D., Harris V.A., Eliasoph L., Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006, 16:249-255.
3. Birnkrant D.J., Bushby K., Amin R.S., et al. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010, 45:739-748.
4. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74(5 (Suppl.)):S70-S92.
5. Moxley R.T., Pandya S., Ciafaloni E., Fox D.J., Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010, 25:1116-1129.
6. Bianchi M.L., Biggar W.D., Bushby K., Rogol A.D., Rutter M., Tseng B. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 2011, 21:298-303.
7. Iannitti T., Capone S., Feder D., Palmieri B. Clinical use of immunosuppressants in Duchenne muscular dystrophy. J Clin Neuromuscul Dis 2010, 12:1-21.
8. King W.M., Ruttencutter R., Nagaraja H.N., et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007, 68:1607-1613.
9. Balaban B., Matthews D.J., Clayton G.H., Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005, 84(11):843-850.
10. LoCascio V., Ballanti P., Milani S., et al. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort. Calcif Tissue Int 1998, 62:199-204.
11. Bachrach L.K. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 2005, 15:86-87.
12. Schoenau E., Frost H.M. The "muscle-bone unit" in children and adolescents. Calcif Tissue Int 2002, 70:405-407.
13. Bothwell J.E., Gordon K.E., Dooley J.M., MacSween J., Cummings E.A., Salisbury S. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr (Phila) 2003, 42:353-356.
14. Henderson R.C., Berglund L.M., May R., et al. The relationship between fractures and DXA measures of BMD in the distal femur of children and adolescents with cerebral palsy or muscular dystrophy. J Bone Miner Res 2010, 25:520-526.
15. Houde S., Filiatrault M., Fournier A., et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008, 38:200-206.
16. Bianchi M.L., Mazzanti A., Galbiati E., et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 2003, 14:761-767.
17. McDonald D., Kinali M., Gallagher A., et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 2002, 44:695-698.
18. Talim B., Malaguti C., Gnudi S., Politano L., Merlini L. Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord 2002, 12:294-295.
19. Biggar W.D., Bachrach L.K., Henderson R.C., Kalkwarf H., Plotkin H., Wong B.L. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005, 15:80-85.
20. Quinlivan R., Shaw N., Bushby K. 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. Neuromuscul Disord 2009, 20:761-769.
21. Leung D.G., Germain-Lee E.L., Denger B.E., Wagner K.R. Report on the Second Endocrine Aspects of Duchenne Muscular Dystrophy Conference December 1-2, 2010, Baltimore, Maryland, USA. Neuromuscul Disord 2011, 21(8):594-601.
22. Bianchi M., Morandi L., Andreucci E., Vai S., Frasunkiewicz J., Cottafava R. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporos Int 2011, 22:529-539.
23. Gauld L.M., Kappers J., Carlin J.B., Robertson C.F. Height prediction from ulna length. Dev Med Child Neurol 2004, 46:475-480.
24. Genant H.K., Wu C.Y., van Kuijk C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993, 8(9):1137-1148.
25. Zemel B.S., Kalkwarf H.J., Gilsanz V., et al. Revised reference curves for bone mineral content and areal Bone mineral density according to age and sex for black and non-black children: results of the Bone Mineral Density in childhood study. J Clin Endocrinol Metab 2011, 96:3160-3169.
26. Söderpalm A.-C., Magnusson P., Åhlander A.-C., et al. Bone mass development in patients with Duchenne and Becker muscular dystrophies: a 4-year clinical follow-up. Acta Paediatr 2012, 101(4):424-432.
27. Manolagas S.C., Weinstein R.S. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999, 14:1061-1066.
28. Weinstein R.S. Clinical practice: glucocorticoid-induced bone disease. N Eng J Med 2011, 365:62-70.
29. Larson C.M., Henderson R.C. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 2000, 20:71-74.
30. Crabtree N.J., Roper H., McMurchie H., Shaw N.J. Regional changes in bone area and bone mineral content in boys with Duchenne muscular dystrophy receiving corticosteroid therapy. J Pediatr 2010, 156(450-455):e451.
31. Sbrocchi A.M., Rauch F., Jacob P., Matzinger M., Ward L.M. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 2012, http://dx.doi.org/10.1007/s00198-012-1911-3 [Epub ahead of print].
32. Siminoski K., O'Keeffe M., Lévesque J., Hanley D., Brown J.P. Canadian association of radiologists technical standards for bone mineral densitometry reporting. Can Assoc Radiol J 2011, 62:166-175.
33. Leonard M.B., Zemel B.S. Current concepts in pediatric bone disease. Pediatr Clin North Am 2002, 49:143-173.
34. Harcke H.T., Kecskemethy H., Conklin D., Scavina M., Mackenzie W., McKay C. Assessment of bone mineral density in Duchenne muscular dystrophy using the lateral distal femur. J Clin Neuromuscul Dis 2006, 8:1-6.
35. Gordon C.M., Bachrach L.K., Carpenter T.O., et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD pediatric official positions. J Clin Densitom 2008, 11(1):43-58.